NUFORMIX PLC

Report Publication Announcement • Feb 14, 2025

National Storage Mechanism | Additional information

RNS Number : 2289X

Nuformix PLC

14 February 2025

14 February 2025

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2024 (the "Annual Financial Report 2024") and the 2025 Notice of Annual General Meeting ("AGM") are today being posted to its shareholders.

A full pdf version of the Annual Financial Report 2024 together with the Notice of AGM will shortly be available for download from the Company's website at: https://nuformix.com/document-center/

The AGM will be held on 20 March 2025 at 10.00 a.m. at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

Nuformix plc Dr Daniel Gooding, Executive Director	Via IFC Advisory
CMC Markets Douglas Crippen	+44 (0) 20 3003 8632
IFC Advisory Limited Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSFLFLSFRISLIE